ClinicaliQ Trial Snapshot
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers — Recruiting • Phase I • Oncology • NCT05873686.
- NXP900 is a first-in-human investigational agent being tested in a dose escalation and expansion study to determine safety, tolerability, and optimal dosing in patients with advanced solid tumors, particularly those with YES1 amplification or other selected genetic alterations.
- Eligible patients include adults with advanced/metastatic solid tumors who have exhausted standard treatment options or for whom no standard therapy exists; the study specifically enriches for tumors with genetic alterations such as YES1 amplification, making it relevant for precision oncology approaches.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Eligibility Snapshot
- Part A Inclusion Criteria: 1. Provide written informed consent. 2. 18 years old or older. 3. Advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator. 4. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.